News | Stroke | May 12, 2017

Analysis Shows Increased Risk of Early Stroke with New-Onset Atrial Fibrillation Post-TAVR

Results of BRAVO-3 randomized trial show patients with new-onset AF are more than four times more likely to have a stroke than non-AF TAVR patients

Analysis Shows Increased Risk of Early Stroke with New-Onset Atrial Fibrillation Post-TAVR, SCAI 2017 late-breaking clinical trial

May 12, 2017 — More than one-third of patients undergoing transcatheter aortic valve replacement (TAVR) were observed to have atrial fibrillation (AF) either at baseline or new-onset within 30 days after TAVR, according to data from the BRAVO-3 randomized trial. Patients with new-onset AF had a greater than 4-fold greater risk of stroke within 30 days. Results from the trial were presented as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2017 Scientific Sessions, May 10-13 in New Orleans.

The BRAVO-3 trial included 802 patients with a mean age of 82 years randomized to bivalirudin (BIV) or unfractionated heparin (UFH) for transfemoral TAVR. In this sub-study, 41.4 percent (n=332) of patients were noted to have baseline AF or new AF within 30 days of TAVR, and 58.6 percent (n=470) had no AF. Patients with existing or new AF had a greater occurrence of pre-existing comorbidities, including renal dysfunction, lower left ventricular ejection fraction and a higher euroSCORE I.

“Previous studies have shown that AF patients undergoing TAVR have a greater risk for ischemic as well as bleeding events,” said the study’s principal investigator George D. Dangas, M.D., Ph.D., professor of medicine at the Icahn School of Medicine at Mount Sinai and director of cardiovascular innovation at the Zena and Michael A. Weiner Cardiovascular Institute of the Mount Sinai Medical Health System in New York City. “We wanted to study these associations using a more contemporary population, in the context of overall improved devices, techniques and post-TAVR management to see if the results were similar. We were also interested in studying the antithrombotic prescription patterns in this high-risk patient population, as there is currently no consensus on the optimal strategy following TAVR.”

The primary endpoint of the BRAVO-3 trial was 48h Bleeding Academic Research Consortium (BARC) type 3b bleeding. For this sub-study, the two main outcomes of interest were stroke and death at 30-days in patients with AF versus no AF. Outcomes were also examined by treatment with bivalirudin (BIV) or unfractionated heparin (UFH).

Unadjusted 30-day clinical outcomes for AF patients were stroke (3.9 percent), death (6 percent) and BARC major bleeding (10.2 percent). Outcomes for non-AF patients were stroke (2.6 percent), death (4.5 percent) and BARC major bleeding (9.4 percent). The unadjusted odds of early stroke in patients with new-onset AF were 4.49 times greater compared to odds in patients with no AF. No significant differences were noted in 30-day outcomes by AF status and anticoagulant strategy.

“Our study showed that a large percentage of patients have AF, either baseline or new-onset,” said study investigator Usman Baber, M.D., assistant professor, medicine, cardiology, Icahn School of Medicine at Mount Sinai. “New-onset AF lends a significantly higher risk of early stroke, nearly five-fold. Moreover, although nearlyall AF patients had a high calculated predictive stroke risk score (CHA2DS2VASc) of ≥ 4, we found that around two-thirds went home on an oral anticoagulant. We need to better risk stratify AF patients during follow-up, when acute risk of bleeding has abated, for prescription of anticoagulants where appropriate.”

Another interesting finding of the BRAVO-3 trial was that the design of the device also plays a role in outcomes. Read the article “Analysis Looks at Role Type of Valve Plays in Patient Outcomes Post-TAVR,” which was also presented at SCAI 2017.

Dangas’s disclosed grants or research support from The Medicines Company. Baber reported no disclosures.

Watch the VIDEO "TAVR Stands Equal to Surgical Valve Replacement," an interview with Michael Reardon, M.D.

For more information: www.scaiscientificsessions.org


Related Content

News | Atrial Fibrillation

July 8, 2024 — Pulsed field ablation (PFA) is safe for treating patients with common types of atrial fibrillation (AF) ...

Home July 08, 2024
Home
News | Atrial Fibrillation

June 12, 2024 — A team of Ochsner Health cardiologists recently published an article in the Journal of the American ...

Home June 12, 2024
Home
News | Atrial Fibrillation

April 18, 2024 — New evidence-based research calls into question the conventional three-month blanking period ...

Home April 18, 2024
Home
News | Atrial Fibrillation

March 28, 2024 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson ...

Home March 28, 2024
Home
News | Atrial Fibrillation

February 27, 2024 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & ...

Home February 27, 2024
Home
News | Atrial Fibrillation

February 6, 2024 — Cortex announced the initiation of its RESOLVE-AF trial (NCT05883631), a study formally launched in ...

Home February 06, 2024
Home
News | Atrial Fibrillation

February 2, 2024 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson ...

Home February 02, 2024
Home
News | Atrial Fibrillation

January 18, 2024 — Abbott announced the first global procedures have been conducted using the company's new Volt Pulsed ...

Home January 18, 2024
Home
News | Atrial Fibrillation

December 29, 2023 — Boston Scientific Corporation has initiated the AVANT GUARD clinical trial to evaluate the safety ...

Home December 29, 2023
Home
News | Atrial Fibrillation

December 26, 2023 — Pulse Biosciences, Inc., a company primarily focused on leveraging its novel and proprietary CellFX ...

Home December 26, 2023
Home
Subscribe Now